» Articles » PMID: 35132899

Thyroid Cancer Incidence and Mortality Trends in the United States: 2000-2018

Overview
Journal Thyroid
Date 2022 Feb 8
PMID 35132899
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer incidence has significantly increased in the United States over the past few decades. Recent studies have suggested a change in thyroid cancer incidence trends following 2013. The main objective of this study was to update the data on thyroid cancer incidence and mortality trends in the United States. Thyroid cancer incidence and incidence-based mortality trends were evaluated using the Surveillance, Epidemiology, and End Results-18 cancer registry. Cases of thyroid cancer diagnosed in 2000-2018 and thyroid cancer deaths during 2000-2018 were included. Annual percent change (APC) was calculated using joinpoint regression analysis. Among 197,070 patients, female (75.6%) and white (81.0%) patients comprised the majority of cases. Papillary thyroid carcinoma (PTC) was the most common histology (89.1%). Incidence rates increased during 2000-2009 (APC 6.80, 95% confidence interval [CI 6.46 to 7.13]) and 2009-2014 (APC 2.58 [CI 1.71 to 3.47]) and then decreased during 2014-2018 (APC -2.33 [CI -3.15 to -1.51]). The incidence trends for PTC overall, localized disease, and tumors ≤1.0 cm mirrored the overall thyroid cancer trends, while incidence rates for regional disease stabilized during 2015-2018 (APC -1.65 [CI -4.09 to 0.84]). The incidence of distant disease decreased during 2015-2018 (APC -17.86 [CI -26.47 to -8.25]). The incidence of tumors ≤1.0 cm decreased (APC -5.83 [CI -7.24 to -4.40]), while the incidence of tumors 1.1-2.0 cm (APC -0.10 [CI -1.16 to 0.96]), 2.1-4.0 cm (APC 1.12 [CI -0.17 to 2.43]), and >4.0 cm (APC -1.13 [CI -4.58 to 2.45]) stabilized during the most recent 4-6 years. Incidence-based mortality increased throughout 2000-2018 (average APC 1.35 [CI 0.88 to 1.82]). Thyroid cancer incidence rates have declined since 2014. Similar declines are noted for PTC, localized disease, and tumors ≤1.0 cm, but not for tumors >2.0 cm. Incidence-based mortality rates continue to increase. These findings suggest that changing patterns in the management of thyroid nodules may have led to a decrease in diagnosis of small indolent tumors, but not more advanced tumors.

Citing Articles

Epidemiology of Thyroid Cancer in Tuscany (Central Italy) 2013-2017: Not Just Overdiagnosis.

Capezzone M, Torregrossa L, Poma A, Cartocci A, Petrone L, Sparano C Cancers (Basel). 2025; 17(5).

PMID: 40075565 PMC: 11899145. DOI: 10.3390/cancers17050717.


Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece.

Simeakis G, Kapama A, Paparodis R, Gkousis P, Koursaros P, Kokkinis C Biomedicines. 2025; 13(2).

PMID: 40002668 PMC: 11852475. DOI: 10.3390/biomedicines13020255.


Nomogram for predicting the risk of cervical lymph node metastases and recurrence in papillary thyroid carcinoma based on the thyroid differentiation score system and clinical characteristics.

Liu Y, Wang X, Sun X, Li H, Wang L BMC Endocr Disord. 2025; 25(1):39.

PMID: 39939864 PMC: 11823047. DOI: 10.1186/s12902-025-01867-7.


Influence factors and survival outcomes of different invasion sites in locally advanced thyroid cancer and new site-based risk stratification system.

Tao Z, Ding Z, Guo B, Fan Y, Deng X Endocrine. 2025; .

PMID: 39934508 DOI: 10.1007/s12020-025-04165-3.


Type 2 Diabetes, Obesity and Their Relation to the Risks of Thyroid Cancer.

Grimmichova T, Kuklikova V, Bulanova B, Pacesova P, Vaclavikova E, Moravcova J Physiol Res. 2025; 73(6):1025-1035.

PMID: 39903892 PMC: 11835217.